Fierce Biotech reports this morning that several heavy hitters are interested in competing in the Onyx sweepstakes. The latest to be dubbed a player by analysts is Pfizer looking to enhance its oncology portfolio with all those Big Bucks it saved while chopping R&D the past couple of years. BMS and Gilead are also reported to be still looking at a deal too.
Other big guys, including Novartis, Sanofi, GSK, Biogen Idec and Bayer are said to have stepped aside. Bayers is still considered a bidder who might be willing to take on part of a deal to gain full access to a couple of drugs it partners with Onyx on.
If we can keep a couple big guys in the game, this will likely even be more fun than Sanofi's pursuit of Genzyme a few years ago as we will have rival suitors around to bid things up? In the Genzyme situation, Termeer had to make his own way in driving up the price for GZ. In this case, Onyx's Tony Coles may get a lot of help directly from the opposing bidders. This should be fun.
Posted by Bruce Lehr July 17th 2013.